<DOC>
	<DOC>NCT02111707</DOC>
	<brief_summary>To determine if the timing of administration of indomethacin affects the primary outcome of post-ERCP pancreatitis (PEP). Patients undergoing ERCP will be randomly assigned to receive pre or post-procedure rectal indomethacin to prevent the occurrence of PEP.</brief_summary>
	<brief_title>Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)</brief_title>
	<detailed_description />
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>All patients referred for ERCP at the University of Alberta Age greater than 18 years Ability to provide written informed consent Acute pancreatitis Active peptic ulcer disease Rectal disease Aspirininduced asthma Nonsteroidal antiinflammatory drug (NSAIDs) induced hypersensitivity Pregnancy Breast feeding Creatinine clearance &lt; 30 ml/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>